Quidel™ Sofia SARS Antigen FIA
The Sofia SARS Antigen Fluorescent Immunoassay (FIA) uses advanced immunofluorescence-based lateral flow technology in a sandwich design for qualitative detection of nucleocapsid protein from SARS-CoV-2. The Sofia SARS Antigen FIA, with the Sofia 2 and Sofia analyzers, provides automated and objective results in 15 minutes, allowing for testing of patients suspected of COVID-19/2019-nCoV in near-patient testing environments.
Please note: a Sofia Analyzer is required in order to use this product.
Advantages
- Results in 15 minutes
- Objective, accurate results
- Easy to use
Other details
- Positive Predictive Value: 100%; Overall Accuracy: 98.5%
- Cannot detect virus until 3rd-4th day of infection
Availability
Depending on volumes, typically available within a week of an approved order being accepted.
More information
For more information, e.g. product info sheets, safety data sheets, pricing and more contact us.
Results in 15 minutes
Rapid results to support efficient dispositioning of patients.
Objective, accurate results
Reliable results without cross-reactivity to seasonal coronaviruses.
Dual work modes
Adjusts to your volume fluctuations. Allows for significant throughput and batching of samples in READ NOW Mode.
Easy to use
Simple test workflow follows a similar format to CLIA-waived Sofia and Sofia 2 assays.
Virena connection
Provides automated tracking, data capture, government reporting, and exclusive disease mapping.
Fluorescent technology with automated read
Objective result that eliminates the subjectivity of a visual read.
Self-contained test cassette
Clean, easy to use and dispose of.
Product Specifications:
Time to results: 15 minutes
Sample type: Direct nasal/nasopharyngeal swabs
Kit storage conditions: Room temperature (15°C to 35°C / 59°F to 86°F)
Controls: Positive and negative, included in kit
PPA: 96.7%
NPA: 100%
Shelf life: 24 months from date of manufacture
CLIA complexity: Waived*
* fda.gov: The settings in which an EUA-authorized test may be used are described in the Letter of Authorization. As discussed in the Guidance for Industry and Other Stakeholders: Emergency Use Authorization of Medical Products and Related Authorities, when the FDA authorizes tests for use at the point of care (including SARS-CoV-2 point of care test systems) under an EUA, such tests are deemed to be CLIA waived tests. Accordingly, for the duration of the emergency declaration, such tests can be performed in a patient care setting that is qualified to have the test performed there as a result of operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.